Oncotype DX Colon Recurrence Score^® test

In the United States, colon cancer is the third most prevalent cancer among men and women. It’s also the second most common cause of cancer-related deaths1—yet no two colon cancer patients, or their treatment needs, are the same. Each patient has an individualized level of risk, making the choice of treatment different for everyone. Part of the treatment decision-making process involves understanding the likelihood of colon cancer returning and how a patient is managed after surgery.

The Oncotype DX Colon Recurrence Score test is clinically validated to quantify the risk of recurrence in patients with anatomic stage II, T3 or T4, MMR-P*, or stage III A/B colon cancers. This 12-gene test—with 7 cancer-related genes and 5 reference genes—looks at the underlying biology of a patient’s tumor, so you can choose a treatment that fits their unique situation.2-5